PMID- 22708030
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20211021
IS  - 2008-8213 (Electronic)
IS  - 2008-7802 (Print)
IS  - 2008-7802 (Linking)
VI  - 3
IP  - 5
DP  - 2012 May
TI  - Immunization against Haemophilus Influenzae Type b in Iran; Cost-utility and 
      Cost-benefit Analyses.
PG  - 332-40
AB  - BACKGROUND: Haemophilus Influenzae type b (Hib) is an important cause of 
      morbidity and mortality in children. Although its burden is considerably 
      preventable by vaccine, routine vaccination against Hib has not been defined in 
      the National Immunization Program of Iran. This study was performed to assess the 
      cost-benefit and cost-utility of running an Hib vaccination program in Iran. 
      METHODS: Based on a previous systematic review and meta-analysis for vaccine 
      efficacy, we estimated the averted DALYs (Disability adjusted life years) and 
      cost-benefit of vaccination. Different acute invasive forms of Hib infection and 
      the permanent sequels were considered for estimating the attributed DALYs. We 
      used a societal perspective for economic evaluation and included both direct and 
      indirect costs of alternative options about vaccination. An annual discount rate 
      of 3% and standard age-weighting were used for estimation. To assess the 
      robustness of the results, a sensitivity analysis was performed. RESULTS: The 
      incidence of Hib infection was estimated 43.0 per 100000, which can be reduced to 
      6.7 by vaccination. Total costs of vaccination were estimated at US$ 15,538,129. 
      Routine vaccination of the 2008 birth cohort would prevent 4079 DALYs at a cost 
      per averted-DALY of US$ 4535. If we consider parents' loss of income and future 
      productivity loss of children, it would save US$ 8,991,141, with a benefit-cost 
      ratio of 2.14 in the base-case analysis. Sensitivity analysis showed a range of 
      0.78 to 3.14 for benefit-to-cost ratios. CONCLUSION: Considering costs per 
      averted DALY, vaccination against Hib is a cost-effective health intervention in 
      Iran, and allocating resources for routine vaccination against Hib seems logical.
FAU - Moradi-Lakeh, Maziar
AU  - Moradi-Lakeh M
AD  - Department of Community Medicine, Knowledge Utilization Research Center, Tehran 
      University of Medical Sciences, Tehran, Iran.
FAU - Shakerian, Sareh
AU  - Shakerian S
FAU - Esteghamati, Abdoulreza
AU  - Esteghamati A
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Int J Prev Med
JT  - International journal of preventive medicine
JID - 101535380
PMC - PMC3372076
OTO - NOTNLM
OT  - Cost-benefit analysis
OT  - Haemophilus Influenzae
OT  - cost-utility analysis
COIS- Conflict of Interest: None declared.
EDAT- 2012/06/19 06:00
MHDA- 2012/06/19 06:01
PMCR- 2012/05/01
CRDT- 2012/06/19 06:00
PHST- 2011/10/04 00:00 [received]
PHST- 2011/12/21 00:00 [accepted]
PHST- 2012/06/19 06:00 [entrez]
PHST- 2012/06/19 06:00 [pubmed]
PHST- 2012/06/19 06:01 [medline]
PHST- 2012/05/01 00:00 [pmc-release]
AID - IJPVM-3-332 [pii]
PST - ppublish
SO  - Int J Prev Med. 2012 May;3(5):332-40.